Drug Profile
PX 102
Alternative Names: Px-102; Px20606Latest Information Update: 16 Sep 2019
Price :
$50
*
At a glance
- Originator Phenex Pharmaceuticals
- Class Small molecules
- Mechanism of Action Farnesoid X-activated receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Metabolic syndrome; Non-alcoholic steatohepatitis
Most Recent Events
- 01 Oct 2012 Phenex Pharmaceuticals completes a phase I trial in Healthy volunteers in Germany (NCT01998672)
- 01 Feb 2012 Phenex Pharmaceuticals initiates enrolment in a phase I trial for Healthy volunteers in Germany (NCT01998672)
- 01 Dec 2011 Phenex Pharmaceuticals completes a phase I trial in Healthy volunteers in Germany (NCT01998659)